MedPath

Tolerability and Satisfaction With Evie

Not Applicable
Completed
Conditions
Infertility
Interventions
Device: Evie Slow-release Insemination Device
Other: Traditional Intrauterine Insemination
Registration Number
NCT01969812
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

The purpose of this study is to determine patient satisfaction and tolerability of the Evie® slow-release insemination device for US population. Additionally, to assess cramping with the device and to determine pregnancy rates using the slow insemination device compared to standard IUI.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
22
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Evie Slow-Release Insemination DeviceEvie Slow-release Insemination DevicePreliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
Traditional Intrauterine InseminationTraditional Intrauterine InseminationTraditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
Primary Outcome Measures
NameTimeMethod
Patient Tolerability and Satisfaction SF361 month

The primary outcome variable will be patient tolerability and satisfaction, based on a standardized SF-36 survey.

Total score 0-100 with higher score denoting better outcomes

Secondary Outcome Measures
NameTimeMethod
Cramping1 month

Cramping assessment based on a Numerical Rating Scale 0 to 10. Higher score denotes worse cramping.

Pregnancy Rates3 months

Pregnancy rates based on blood and urine beta-HCG.

Trial Locations

Locations (1)

Women's Institute at Carolinas Medical Center

🇺🇸

Charlotte, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath